Objective: To evaluate disease status after 20 years in a cohort defined as "benign multiple sclerosis (MS)" (Expanded Disability Status Scale [EDSS] score < or = 3) at 10 years from onset.
Methods: Patients with an EDSS score < or = 3 at 10 (+/- 1) years from onset were selected from the British Columbia MS clinic database. The 20-year EDSS score was the primary outcome. Potential risk factors differentiating those who "continued benign" (EDSS score < or = 3.0) from those who were "no longer benign" (EDSS score > 3.0) at 20 years, including age at onset, onset symptoms, and 10-year EDSS score, were analyzed, and lower 10-year EDSS score cutoffs were investigated.
Results: Twenty-year EDSS scores were obtained for 169 of 200 patients (84.5%); of these, 88 (52.1%) continued benign, but 36 (21.3%) progressed to require the use of a cane (EDSS score > or = 6). Conversion to secondary progressive MS occurred in 45 of 196 patients (23%) with a relapsing-remitting onset. The only variable associated with disease progression at 20 years was the 10-year EDSS score (p < 0.0005); no 10-year EDSS score seemed ideal in predicting benign status, and an EDSS score < or = 2 resulted in 32% becoming no longer benign.
Discussion: At 10 years from onset, neither an Expanded Disability Status Scale (EDSS) score < or = 3 nor an EDSS score < or = 2 adequately represented "benign multiple sclerosis (MS)" because an appreciable proportion of patients progressed in disease severity. Appropriate and reliable criteria to identify which patients with MS remain with mild disability over the long term have yet to be determined.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1212/01.wnl.0000253185.03943.66 | DOI Listing |
Acta Parasitol
January 2025
Vector-borne Diseases Research Center, North Khorasan University of Medical Sciences, P.O. Box: 9453155166, Bojnurd, Iran.
Pourpose: This study aimed to investigate the seroepidemiological status of Toxoplasma gondii (T. gondii) infection in Multiple Sclerosis (MS) patients compared to controls.
Methods: The present study included 98 MS patients and 100 controls.
Front Immunol
January 2025
Department of Neurology, The Second Affiliated Hospital, Army Medical University, Chongqing, China.
Objective: To investigate the differences of clinical characteristics and treatment outcomes between paraneoplastic neurologic syndrome (PNS) patients with one high-risk antibody and patients with two high-risk antibodies.
Methods: We retrospectively analyzed the data of 51 PNS patients with high-risk antibody. Clinical data were extracted from the patients' electronic medical records.
Behav Neurol
January 2025
Neurology, Public Health and Disability Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Multiple sclerosis (MS) is the most common cause of disability in young adults due to several motor, sensory, and cognitive symptoms. However, little is still known about the impact of psychological, cognitive, and social-support variables on subjective disability. This study is aimed at exploring the role of clinical, psychological, cognitive, and social-support variables in predicting disability levels as perceived by persons with multiple sclerosis (pwMS).
View Article and Find Full Text PDFMult Scler Relat Disord
January 2025
Department of Neurology, School of Medicine, Washington University in St. Louis, 660 South Euclid Avenue, St Louis, MO 63110, USA. Electronic address:
Background: Prognostic biomarkers at multiple sclerosis (MS) onset to predict disease severity may help guide initial therapy selection for people with MS. Over 20 disease-modifying treatments (DMTs) of varying levels of risk and efficacy now exist. The ability to predict MS severity would help to identify those patients at higher risk where a highly effective, but potentially risky, therapy would be optimal.
View Article and Find Full Text PDFMult Scler Relat Disord
January 2025
Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Background: Oculomotor abnormalities are common in multiple sclerosis (MS) but are not quantitatively evaluated in clinical practice. Oculometric measures (OMs) are characteristics of eye movements captured while performing a visual task, e.g.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!